Redmile Group LLC Takes $3.42 Million Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Redmile Group LLC acquired a new stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 310,884 shares of the biotechnology company’s stock, valued at approximately $3,423,000.

Several other institutional investors have also modified their holdings of ATXS. FMR LLC lifted its holdings in shares of Astria Therapeutics by 29.2% during the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after purchasing an additional 1,767,714 shares during the last quarter. Vestal Point Capital LP lifted its holdings in shares of Astria Therapeutics by 23.1% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after purchasing an additional 750,000 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Astria Therapeutics by 23.4% during the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock valued at $35,693,000 after purchasing an additional 480,184 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Astria Therapeutics by 13.5% during the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock valued at $16,763,000 after purchasing an additional 218,518 shares during the last quarter. Finally, Affinity Asset Advisors LLC lifted its holdings in shares of Astria Therapeutics by 15.4% during the second quarter. Affinity Asset Advisors LLC now owns 975,606 shares of the biotechnology company’s stock valued at $8,878,000 after purchasing an additional 130,000 shares during the last quarter. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Price Performance

Shares of ATXS stock opened at $10.14 on Thursday. Astria Therapeutics, Inc. has a fifty-two week low of $4.75 and a fifty-two week high of $16.90. The stock’s 50-day moving average is $11.02 and its two-hundred day moving average is $10.65. The firm has a market cap of $572.24 million, a P/E ratio of -4.85 and a beta of 0.67.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Wedbush reaffirmed an “outperform” rating and set a $22.00 target price on shares of Astria Therapeutics in a report on Tuesday, August 13th. Evercore ISI raised Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. Oppenheimer upped their price target on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $25.60.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.